Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033 1 TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE)-- ...
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on ...
TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE)-- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer ...
Key findings presented at the Keystone Symposia on Obesity Therapeutics SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today reported ...
Key findings presented at the Keystone Symposia on Obesity Therapeutics insitro, the AI therapeutics company built on causal biology, today reported research demonstrating that artificial intelligence ...
Lansing — A nonprofit organization that formed in December has launched an ad blitz in recent days attacking U.S. Rep. John James and possibly signalling a new candidate could be waiting in the wings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results